A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients With CLL Who Are Intolerant to Prior BTK or PI3K delta Inhibitor Therapy

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [1] A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy.
    Mato, Anthony R.
    Schuster, Stephen J.
    Lamanna, Nicole
    Flinn, Ian
    Barrientos, Jacqueline Claudia
    Kambhampati, Suman
    Cheson, Bruce D.
    Barr, Paul M.
    Pagel, John M.
    Reeves, James Andrew
    Lansigan, Frederick
    Pu, Jeffrey J.
    Skarbnik, Alan P.
    Fonseca, Gustavo A.
    Dorsey, Colleen
    Prak, Eline Luning
    Paskalis, Dana
    Sportelli, Peter
    Miskin, Hari P.
    Brander, Danielle M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy
    Mato, Anthony R.
    Cheson, Bruce D.
    Lamanna, Nicole
    Pagel, John M.
    Lansigan, Frederick
    Barr, Paul M.
    Pu, Jeffrey J.
    Dorsey, Colleen
    Chatburn, Elizabeth T.
    Svoboda, Jakub
    Schuster, Stephen J.
    Luning-Prak, Eline
    Tsao, Patricia
    Sitlinger, Andrea
    Ujjani, Chaitra S.
    Paskalis, Dana
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Brander, Danielle M.
    BLOOD, 2017, 130
  • [3] Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy
    Mato, Anthony R.
    Ghosh, Nilanjan
    Schuster, Stephen J.
    Lamanna, Nicole
    Pagel, John M.
    Flinn, Ian W.
    Barrientos, Jacqueline C.
    Rai, Kanti R.
    Reeves, James A.
    Cheson, Bruce D.
    Barr, Paul M.
    Kambhampati, Suman
    Lansigan, Frederick
    Pu, Jeffrey J.
    Skarbnik, Alan P.
    Roeker, Lindsey
    Fonseca, Gustavo A.
    Sitlinger, Andrea
    Hamadeh, Issam S.
    Dorsey, Colleen
    LaRatta, Nicole
    Weissbrot, Hanna
    Prak, Eline T. Luning
    Tsao, Patricia
    Paskalis, Dana
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Svoboda, Jakub
    Brander, Danielle M.
    BLOOD, 2021, 137 (20) : 2817 - 2826
  • [4] KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy.
    Dorsey, Colleen
    Paskalis, Dana
    Brander, Danielle M.
    Lansigan, Frederick
    Barr, Paul M.
    Lamanna, Nicole
    Cheson, Bruce D.
    Pu, Jeffrey J.
    Schreeder, Marshall T.
    Pagel, John M.
    Sportelli, Peter
    Fanning, Molly J.
    Miskin, Hari P.
    Zimmer, Tracey
    Walsh, Kristy
    Schuster, Stephen J.
    Luning-Prak, Eline T.
    Wileyto, E. Paul
    Weiss, Michael S.
    Mato, Anthony R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202
    Maharaj, Kamira Karen
    Powers, John J.
    Pabon-Saldana, Mibel
    Fonseca, Renee
    Achille, Alex
    Deng, Susan
    Miskin, Hari P.
    Maryanski, Dave
    Sahakian, Eva
    Pinilla-Ibarz, Javier
    BLOOD, 2016, 128 (22)
  • [6] Clinical activity and safety profile of TGR-1202, a novel once daily PI3Kδ inhibitor, in patients with CLL and B-cell lymphoma.
    Burris, Howard A.
    Patel, Manish R.
    Fenske, Timothy S.
    O'Connor, Owen A.
    Deng, Changchun
    Brander, Danielle M.
    Gutierrez, Martin
    Jones, Suzanne Fields
    Kuhn, John G.
    Miskin, Hari P.
    Sportelli, Peter
    Vakkalanka, Swaroop V. S.
    Flinn, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] An Integrated Safety Analysis of the Next Generation PI3Kd Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
    Davids, Matthew S.
    Flinn, Ian W.
    Mato, Anthony R.
    O'Connor, Owen A.
    Brander, Danielle M.
    Lunning, Matthew A.
    Vose, Julie M.
    Nastoupil, Loretta
    Fowler, Nathan
    Flowers, Christopher
    Brown, Jennifer R.
    Schreeder, Marshall T.
    Ghosh, Nilanjan
    Lansigan, Frederick
    Cheson, Bruce D.
    Barr, Paul M.
    Pagel, John M.
    Danilov, Alexey
    Pinilla-Ibarz, Javier
    Deng, Changchun
    Burke, John M.
    Siddiqi, Tanya
    Patel, Manish R.
    Farber, Charles M.
    Venugopal, Parameswaran
    Gribben, John G.
    Zinzani, Pier Luigi
    Miskin, Hari P.
    Sportelli, Peter
    Weiss, Michael S.
    O'Brien, Susan M.
    BLOOD, 2017, 130
  • [8] Umbralisib/TGR-1202 As a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas
    Pal, Ipsita
    Kim, Yu Ri
    Scotto, Luigi
    Lipstein, Mark R.
    Ali, Abdullah Mahmood
    Mukherjee, Siddhartha
    Bates, Susan E.
    O'Connor, Owen A.
    Deng, Changchun
    BLOOD, 2017, 130
  • [9] LONG-TERM FOLLOW-UP OF THE NEXT GENERATION PI3K-DELTA INHIBITOR TGR-1202 DEMONSTRATES SAFETY AND HIGH RESPONSE RATES IN CLL: INTEGRATED-ANALYSIS OF TGR-1202 MONOTHERAPY AND COMBINED WITH UBLITUXIMAB
    Mato, A.
    Burris, H. A., III
    Flinn, I.
    Lunning, M.
    Vose, J.
    Fowler, N.
    Nastoupil, L.
    O'Brien, S.
    Schreeder, M. T.
    Patel, M. R.
    Fenske, T. S.
    Brander, D. M.
    Siddiqi, T.
    Flowers, C.
    Burger, J. A.
    Wierda, W. G.
    Kuhn, J. G.
    Sportelli, P.
    Miskin, H.
    Weiss, M. S.
    O'Connor, O. A.
    HAEMATOLOGICA, 2016, 101 : 50 - 51
  • [10] TGR-1202, a Novel Once Daily PI3K-Delta Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma
    O'Connor, Owen A.
    Flinn, Ian W.
    Patel, Manish R.
    Fenske, Timothy S.
    Deng, Changchun
    Brander, Danielle M.
    Gutierrez, Martin
    Jones, Suzanne
    Kuhn, John G.
    Miskin, Hari P.
    Sportelli, Peter
    Vakkalanka, Swaroop
    Burris, Howard A., III
    BLOOD, 2015, 126 (23)
12345